Navigation Links
AlphaDetail AlphaPulse™: Anticipated Impact of CATT Trial in Wet AMD Treatment

SAN MATEO, Calif., May 16, 2011 /PRNewswire/ -- On April 28, 2011 the New England Journal of Medicine released highly anticipated one-year results of the ongoing "Comparisons of Age-Related Macular Degeneration Treatments Trials" (CATT).

AlphaDetail, Inc., a leader in global ophthalmology primary market research and influence network mapping, has conducted its latest AlphaPulse survey with 120 Ophthalmologists to gauge their reactions on the heels of this important news.

Amy Tsang, a Director at AlphaDetail, explained, "The use of Avastin vs. Lucentis in Wet AMD has been debated among eye care professionals for years, and many anticipated that these results could bring closure to the issue."

While results from the trial confirmed that Avastin is non-inferior to Lucentis on visual acuity efficacy measures, the results related to level of risk associated with serious adverse events are less definitive.

  • 68% of surveyed Ophthalmologists are currently aware of the CATT trial results.
  • Perceived Benefits of Avastin
    • Over three-quarters of Ophthalmologists agree that the results from the CATT trial provide evidence that Avastin's cost savings outweigh its potential risks in Wet AMD.
    • Avastin is currently the dominant anti-VEGF therapy used to treat Wet AMD in the United States and this dominance is expected to continue among newly diagnosed patients in the future.
    • Based on the CATT trial results, Ophthalmologists intend to switch10-15% of their Wet AMD patients currently on Lucentis to Avastin over the next 6 months.

  • Perceived Benefits of Lucentis
    • Two-thirds of Ophthalmologists agree that Lucentis' superiority over Avastin in other efficacy-related attributes, such as lowering retinal thickness and decreasing retinal fluid, are important considerations when selecting the appropriate therapy for their patients.
    • Similarly, two-thirds of Ophthalmologists agree that data supporting equivalent long term efficacy between Lucentis and Avastin is still needed.
    • Finally, Ophthalmologists are divided on their level of concern about mortality rates and risk of hemorrhagic stroke with Avastin compared to Lucentis as shown in an analysis of 77,886 Wet AMD patients on Medicare.

To learn more about this study and to receive full results, please contact Amy Tsang at or (650) 581-3127.

About AlphaDetail, Inc.:

At AlphaDetail, we have an unparalleled commitment to our clients. We are a full-service primary market research firm, with a particular emphasis in large and complex quantitative studies for the global healthcare community. AlphaDetail is built on one of the industry's strongest foundations that includes a large team of exceptional analytical specialists, the industry's leading technology platform and a flexible approach to research that helps us to answer our clients' most challenging questions.

SOURCE AlphaDetail, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. AlphaDetail AlphaPulse(TM): Most Practicing Physicians React Positively to FDA Panels Recommendation for Additional Cardiovascular Safety Trials for New Diabetes Medications.
2. AlphaDetail Tracking Study Enhancements: The Advantage of Integration and Speed
3. AlphaDetail, Inc. Enhances Methodology / Advanced Analytics Capabilities
4. AlphaDetail Revenue Soars 30% in 2010
5. AlphaDetail Commemorates 10-Year Anniversary by Community Volunteering
6. Medivation Announces Organizational Changes to Support Anticipated Growth and Future Commercialization
7. Despite Managed Care Obstacles, Interest and Anticipated Use of Centocor Ortho-Biotechs New Psoriasis Agent Stelara (ustekinumab) is High
8. New Mexico Software Enhances Technology Staff to Support Anticipated Sales Growth
9. TIGR® Matrix Surgical Mesh - Exhibited Ahead of Anticipated CE Mark Approval at European Hernia Society 2011, Ghent, Belgium
10. Hopkins Report: Focusing on Family Planning Lessens HIV Impact
11. Dendreon Completes Target Enrollment of 500 Patients in Phase 3 IMPACT Study of Provenge(R) For Advanced Prostate Cancer
Post Your Comments:
(Date:10/2/2017)... , Oct. 2, 2017  AllianceRx Walgreens Prime, the ... by Walgreens and pharmacy benefit manager Prime Therapeutics LLC ... brand, which included the unveiling of new signage at ... as well as at a few other company-owned facilities ... brand to patients, some of whom will begin to ...
(Date:10/2/2017)... 2017 The Rebound mobile app is poised to ... the tide of prescription drug addiction. The app empowers users ... and stepping down their dosage in a safe, controlled manner ... 2017; the first 100,000 people to sign up will enjoy ... ...
(Date:9/28/2017)... 2017 Cohen Veterans Bioscience and Early Signal ... wearable and home sensors for real-time monitoring of patients ... a nonprofit organization focused on disruptive health solutions for ... analytical system to record and integrate behavioral, cognitive, physiological ... ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... ProVest Insurance Group, a ... Miami, and Raleigh regions, is organizing an extended charity drive to benefit the ... chromosome abnormality. , After struggling since birth with several health challenges, T.J. was ...
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... The American ... to become its next President and Chief Executive Officer, succeeding Dr. James C. Puffer ... Elect beginning July 1, 2018 until Dr. Puffer’s retirement at the end of 2018. ...
(Date:10/13/2017)... ... October 13, 2017 , ... Lori R. Somekh, founder of the Law ... organization of elder law and special needs planning attorneys. “Membership in ElderCounsel helps our ... a forum to network with elder law attorneys nationwide,” said Somekh. , ...
(Date:10/13/2017)... ... October 13, 2017 , ... Ellevate Network, the leading ... to advocate for action towards gender equality at their inaugural Summit in New York ... globe, and reached a social audience of over 3 million. To watch the Mobilize ...
(Date:10/13/2017)... Fairfax, VA (PRWEB) , ... October 13, 2017 ... ... provider of DevOps and Agile Software Development, has been awarded a contract by ... (EATS) Blanket Purchase Agreement (BPA) aims to accelerate the enterprise use of Agile ...
Breaking Medicine News(10 mins):